Neumora (NASDAQ: NMRA) director receives 80,000 stock options grant

Rhea-AI Filing Summary

Neumora Therapeutics director Ho Maykin received a grant of stock options for 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ho Maykin

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	80,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 80,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 80,000 options Exercise price: $1.86 per share Underlying shares: 80,000 shares +2 more

5 metrics

Options granted 80,000 options Stock Option (Right to Buy) grant to director Ho Maykin

Exercise price $1.86 per share Conversion or exercise price for the stock options

Underlying shares 80,000 shares Common Stock underlying the option grant

Options after transaction 80,000 options Total derivative securities held following transaction

Expiration date May 26, 2036 Option term end date

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Annual Meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting financial

"vest on the earlier of ... or (ii) immediately prior to the next Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ho Maykin

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.86	05/27/2026		A		80,000		(1)	05/26/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

	/s/ Michael Milligan, as Attorney-in-Fact for Maykin Ho	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Neumora Therapeutics (NMRA) director Ho Maykin report on this Form 4?

Ho Maykin reported receiving a grant of stock options for 80,000 shares of Neumora Therapeutics common stock. These options are a form of equity compensation, giving the director the right to buy shares at a fixed price in the future.

What is the exercise price of the Neumora (NMRA) stock options granted to Ho Maykin?

The stock options granted to Ho Maykin have an exercise price of $1.86 per share. This price is what must be paid per share to convert the options into common stock once they are vested and exercisable.

How many Neumora Therapeutics (NMRA) options does Ho Maykin hold after this grant?

Following this grant, Ho Maykin holds 80,000 stock options related to Neumora Therapeutics common stock. This filing shows the post-transaction option position from this grant, with no other derivative holdings listed in the provided data.

When do Ho Maykin’s Neumora (NMRA) stock options vest according to the Form 4?

All of Ho Maykin’s options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately prior to the next Annual Meeting following that date, as specified in the footnote.

What is the expiration date of the Neumora (NMRA) stock options granted to Ho Maykin?

The stock options granted to Ho Maykin expire on May 26, 2036. After this date, any unexercised options will lapse and can no longer be used to purchase Neumora Therapeutics common stock.

Was this Neumora (NMRA) Form 4 a stock purchase or a compensation grant?

This Form 4 reflects a grant of stock options as compensation, coded as a “Grant, award, or other acquisition.” It does not show an open-market stock purchase or sale of Neumora Therapeutics shares.